3 ms·
Apheresis, HMG-CoA reductase inhibition (statins), PCSK9 inhibition (-cumabs), and NPC1L1 inhibition (ezetimibe) all lead to reduced LDL-C. Statins and ezetimib
by carbocation 10y ago
Apheresis, HMG-CoA reductase inhibition (statins), PCSK9 inhibition (-cumabs), and NPC1L1 inhibition (ezetimibe) all lead to reduced LDL-C. Statins and ezetimibe lead to reduced MACE and death. The -cumabs should be reporting trial results in the next 12 months, but the genetic data strongly suggests that they will reduce mortality.
Unusual for cholesterol modification agents, some of the CETP drugs (which were designed around their HDL-C raising properties but do lower LDL-C) increased MACE, while others had neutral effect, so there is something about CETP that we have yet to understand.
- tcj_phx 10y agoI can't match you on credentials or acronyms, but I'm pretty good at figuring out what matters for improving my own health. "Should cardiologists evaluate their obsession with LDLs and HDLs?" - http://www.kevinmd.com/blog/2016/04/should-cardiologists-evaluate-their-obsession-with-ldls-and-hdls.html?pop=0&ba=1 http://www.kevinmd.com/blog/2016/04/should-cardiologists-eva... (April 2016) Saw this link on the sidebar: "Slow Medicine: Pressing Pause on Statins For Primary Prevention" - http://www.medpagetoday.com/Blogs/SlowMedicine/61836 http://www.medpagetoday.com/Blogs/SlowMedicine/61836 (December 4 2016) I would estimate that the cholesterol fetish has about 2 more years before it begins to slide into irrelevance, and the field begins to refocus on the causes behind the symptom. A classic fun movie clip: https://www.youtube.com/watch?v=02Or-Hx3yqc https://www.youtube.com/watch?v=02Or-Hx3yqc